Study identification

PURI

https://redirect.ema.europa.eu/resource/44292

EU PAS number

EUPAS39579

Study ID

44292

Official title and acronym

A Prospective and Retrospective, Observational Multicentre Ibalizumab Study of Efficacy (PROMISE)

DARWIN EU® study

No

Study countries

Austria
Belgium
France
Germany
Italy
Netherlands
Norway
Portugal
Spain
Switzerland
United Kingdom

Study status

Ongoing
Research institutions and networks

Institutions

Networks

NEAT ID Foundation

Contact details

Graeme Moyle

Primary lead investigator
Study timelines

Date when funding contract was signed

Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Theratechnologies Europe Limited
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable